1.) Rabeprazole: – Rabeprazole belongs to a class of anti secretory compounds (substituted benzimidazole proton-pump inhibitors) that do not exhibit anticholinergic or histamine H2-receptor antagonist properties, but suppress gastric acid secretion by inhibiting the gastric H+/K+ATPase (hydrogen-potassium adenosine triphosphatase) at the secretory surface of the gastric parietal cell. Because this enzyme is regarded as the acid (proton) pump within the parietal cell, rabeprazole has been characterized as a gastric proton-pump inhibitor. Rabeprazole blocks the final step of gastric acid secretion. In gastric parietal cells, rabeprazole is protonated, accumulates, and is transformed to an active sulfenamide. When studied in vitro, rabeprazole is chemically activated at pH 1.2 with a half-life of 78 seconds.
2.) Levosulpride: – Levosulpiride is more selective and acts primarily as a dopamine D2 antagonist. The prokinetic effect of Levosulpiride is mediated through the blockade of enteric (neuronal and muscular) inhibitory dopamine D2 receptors. Results also show that levosulpiride also acts as a moderate agonist at the 5-HT receptor. The serotonergic (5-HT4) component of Levosulpiride may enhance its therapeutic efficacy in gastrointestinal disorders. This property, together with antagonism at D2 receptors, may contribute to its gastrointestinal prokinetic effect.
1. Absorption: Absolute bioavailability is approximately 52%.
2. Route of Elimination: Following a single 20 mg oral dose of 14C-labeled rabeprazole, approximately 90% of the drug was eliminated in the urine, primarily as thioether carboxylic acid; its lucuronide, and mercapturic acid metabolites.
3. Levosulpride: – Absorption: Oral bioavailability is about 30%; peak plasma concentrations after about 3hr.
4. Route of Elimination: Mainly via urine. Plasma half-life: 9.7 hr (oral); 4.3 hr (IV).
INDICATIONS: Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD). Maintenance of Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD) Healing of Duodenal Ulcers Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome. Irritable bowel syndrome Chronic Gastritis.
BAREC-LS is the combination of Rabeprazole & Levosulpiride Capsules which are a medication used to treat illnesses such as Irritable Bowel Syndrome, Digestive problems, Gastroesophageal Reflux Disease, Mental Disorder, Anxiety, Frequent Persistent Heartburn, and others. Levosulpiride is a prokinetic drug that stimulates the release of acetylcholine, a chemical messenger. This promotes stomach and intestinal motility and reduces acid reflux. Rabeprazole is a proton pump inhibitor that works by lowering the quantity of acid in the stomach, which aids in the treatment of acid reflux and ulcers.
Precautions For Rabeprazole & Levosulpiride Capsules
Rabeprazole and Levosulpiride Capsules should be taken one hour before a meal, ideally in the morning. In severe cases, take it once a day. In severe cases, take twice a day, but only if prescribed by a doctor. Because it is taken on an empty stomach, it may cause renal or other problems. It is only harmful to people who have organ problems. Inform the doctor about the patient’s medical history.
Side Effects Of Rabeprazole & Levosulpiride Capsules
Rabeprazole & Levosulpiride Capsules may cause some side effects such as upset stomach. However, there are very rare chances it causes side effects, if in any case it causes serious side effects then let the doctor know immediately.
Soigner Pharma is one of the well-known pharma companies that deal with both franchise business as well as manufacturing. The company is ISO certified and manufactures the products as per the norms set by WHO and GMP to match the global standard of the products. Moreover, Soigner Pharma is a well recognized third party Rabeprazole and Levosulpiride Capsules manufacturer and supplier in India. We also offer PCD Pharma Franchise for Rabeprazole and Levosulpiride Capsules with complete monopoly rights.